Literature DB >> 15638048

Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis.

M Beon1, R A Harley, A Wessels, R M Silver, A Ludwicka-Bradley.   

Abstract

OBJECTIVE: Scleroderma (SSc) is an autoimmune connective tissue disorder characterized by progressive fibrosis of the skin and internal organs. The leading cause of death in SSc patients is pulmonary dysfunction as a result of interstitial fibrosis and pulmonary vasculopathy. Our objective was to evaluate histopathological abnormalities associated with the development of pulmonary fibrosis in SSc.
METHODS: Postmortem SSc lung tissue from various stages of fibrosis and tissue from normal lung were analyzed by Masson's trichrome staining and immunohistochemistry. Monoclonal antibodies against smooth muscle-alpha actin (myofibroblast marker), von Willebrand Factor, platelet endothelial cell adhesion molecule-1 (endothelial cell markers), or caldesmon (smooth muscle cell marker) were employed.
RESULTS: We found that in the early active stages of SSc lung fibrosis two major types of cellular abnormalities occur. One is the induction of a large number of smooth muscle alpha-actin-positive myofibroblasts in interstitia. The other is the excessive formation of alveolar capillaries (hypervascularity) accompanied by an increase in the number of microvascular endothelial cells. The vascular abnormality also involves the development of microvessels that are irregular in size and shape. However, the population of myofibroblasts and capillary endothelial cells decline as the fibrosis progresses to its most marked, later stages.
CONCLUSION: We conclude that the induction of myofibroblasts and the overdevelopment of capillary microvessels characterize the progression of lung fibrosis in SSc. Using these histological alterations as criteria, therefore we have divided the fibrosis formed in the SSc lungs into four pathological stages. These results suggest that both fibroblast overproliferation and vascular abnormality play an important role in the pathogenesis of lung fibrosis in SSc.

Entities:  

Mesh:

Year:  2004        PMID: 15638048

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  29 in total

Review 1.  Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors:  Maria Trojanowska
Journal:  Nat Rev Rheumatol       Date:  2010-06-29       Impact factor: 20.543

2.  Cyclophosphamide Pulse Therapy Normalizes Vascular Abnormalities in a Mouse Model of Systemic Sclerosis Vasculopathy.

Authors:  Takashi Yamashita; Yoshihide Asano; Ryosuke Saigusa; Takashi Taniguchi; Megumi Hirabayashi; Takuya Miyagawa; Kouki Nakamura; Shunsuke Miura; Ayumi Yoshizaki; Maria Trojanowska; Shinichi Sato
Journal:  J Invest Dermatol       Date:  2018-11-30       Impact factor: 8.551

3.  Neovascular capacity of endothelial progenitor cells in the adult pulmonary circulation.

Authors:  Susan Majka; Diego F Alvarez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-04-03       Impact factor: 5.464

4.  Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.

Authors:  Anagha A Divekar; Dinesh Khanna; Fereidoun Abtin; Paul Maranian; Rajeev Saggar; Rajan Saggar; Daniel E Furst; Ram Raj Singh
Journal:  Clin Immunol       Date:  2011-09-05       Impact factor: 3.969

5.  Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts.

Authors:  Galina S Bogatkevich; Anna Ludwicka-Bradley; Richard M Silver
Journal:  Arthritis Rheum       Date:  2009-11

Review 6.  Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  Ivan O Rosas; Paul F Dellaripa; David J Lederer; Dinesh Khanna; Lisa R Young; Fernando J Martinez
Journal:  Ann Am Thorac Soc       Date:  2014-04

7.  Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.

Authors:  Dinesh Khanna; James R Seibold; Athol Wells; Oliver Distler; Yannick Allanore; Chris Denton; Daniel E Furst
Journal:  Curr Rheumatol Rev       Date:  2010-05-01

Review 8.  Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Authors:  Karen Au; Dinesh Khanna; Philip J Clements; Daniel E Furst; Donald P Tashkin
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 9.  Raynaud phenomenon and digital ulcers in systemic sclerosis.

Authors:  Michael Hughes; Yannick Allanore; Lorinda Chung; John D Pauling; Christopher P Denton; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2020-02-25       Impact factor: 20.543

Review 10.  Histopathology and bronchoalveolar lavage.

Authors:  R M Silver; A U Wells
Journal:  Rheumatology (Oxford)       Date:  2008-10       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.